期刊文献+

PAI-2基因多态性与冠心病的相关性研究

Association between PAI-2 gene polymorphism and coronary heart disease
下载PDF
导出
摘要 目的:探讨PAI-2基因多态性与汉族家族性冠心病的关系。方法:采用聚合酶链反应一限制性片段长度多态性分析(PCR—RFLP)对57例汉族家族性冠心病病人(冠心病组)以及62名汉族无冠心病家族史的健康人(对照组)的PAI-2基因型和等位基因频率分布进行分析,研究它与冠心病的相关性。结果:PAI-2基因Ser/Cys^413(15588位点)G/C多态性等位基因频率在冠心病组和对照组间的分布均有显著性差异(P〈0.05)。Logistic回归分析显示:CC、GG基因型与冠心病相关,且CC是冠心病发病的危险因素(OR=2.405,95%CI:1.059~5.667),GG是冠心病发病的保护性因素(OR:0.303,95%CI:0.089~1.029)。等位基因频率的相对风险分析发现,C等位基因携带者患冠心病的风险是G等位基因的28.88倍(OR=28.88,95%CI:1.96~437.62)。结论:PAI-2基因Ser/Cys^413(15588)G/C多态性与冠心病的发病具有相关性,其中C等位基因是冠心病发病的遗传易感因素,而G等位基因是冠心病发病的保护因素。 Objective: To study the allele frequencies and genotype distribution of the PAI-2 gene in Chinese patients with coronary heart disease(CHD) , and analyze the association between the PAI-2 gene polymorphism and CHD. Methods:The polymorphism of the PAI-2 gene was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 57 patients with CHD and familial history and 62 healthy controls without CHD or familial history to research into the influence of the gene polymorphism on CHD. Results:The distribution of the PAI-2 gene Ser/Cys^413 15588 G/C polymorphism was significantly different between the CHD group and the control group (P〈0.05). The allele frequencies distribution between the 2 groups was also different (P〈0.05). The relative risks of different genotypes for CHD were.. CC was a risk factor for CHD (OR = 2. 405, 95%CI:1. 059-5. 667), GG was a protective factor for CHD(OR = 0. 303, 95% CI: 0. 089-1. 029). The relative risk in C allele carriers was 28.88 times as high as that in G allele carriers (OR =28.88, 95% CI: 1. 96-437. 62). Conclusions:The PAI-2 gene Ser/Cys^413 15588 G/C polymorphism is associated with CHD, the C allele is a risk factor for CHD and the G allele is a protective factor for CHD.
出处 《国际心血管病杂志》 2008年第5期312-315,共4页 International Journal of Cardiovascular Disease
关键词 冠状动脉粥样硬化性心脏病 PAI-2基因 基因多态性 Coronary heart disease PAI-2 gene Gene polymorphism
  • 相关文献

参考文献8

  • 1[1]Topoi EJ.The genomie basis of myocardial infarction[J].J Am Coll Cardiol,2005,46(8):1456-1465.
  • 2[2]Webb AC,Collins KL,Snyder SE,et al.Human monocyte Arg-Serpin cDNA Sequence,chromosomal assignment,and homology to plasminogen activator-inhibitor[J].J Exp Med,1987,166(1):77-94.
  • 3[3]Kruithof EK,Baker MS,Bunn CL.Biological and clinical aspects of plaminogen activator inhibitor type 2[J].Blood,1995,86 (11):4007-4024.
  • 4[4]Antalis TM,Clark MA,Barnes T,et al.Cloning and expression of a eDNA coding for a human monocyte-derived plasminogen activator inhibitor[J].Proc Natl Acad Sci USA,1988,85(4):985-889.
  • 5[5]Ye RD,Wun TC,Sadler JE.eDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta[J].J Biol Chem,1987,262 (8):3718-3725.
  • 6[6]Buyru N,Altinisik J,Gurel CB,et al.PCR-RFLP detection of PAI-2 variants in myocardial infarction[J].Clin Appl Thromb Hemost,2003,9(4):333-336.
  • 7[7]Foy CA,Grant PJ.PCR-RFLP detection of PAI-2 gene variants:prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography[J].Thromb Haemost,1997,77(5):955-958.
  • 8[8]McCarthy JJ,Parker A,Salem R,et al.Large scale association analysis for identification of genes underlying premature coronary heart disease:cumulative perspective from analysis of 111 candidate genes[J].J Med Genet,2004,41(5):334-341.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部